Semaglutide injection site pain compared across two pen devices and formulations in healthy volunteers

Type 2 Diabetes and obesity are chronic conditions requiring long-term management, often involving daily or weekly injectable medications like semaglutide. Patient adherence is critical for treatment success, but injection site pain or discomfort can be a significant barrier, impacting quality of life and compliance. Optimizing the injection experience, through factors like pen design and drug formulation, is crucial for improving patient satisfaction and ensuring consistent medication use. This study addresses the need to minimize injection-related discomfort for semaglutide users.

This clinical trial enrolled 104 healthy men and women to compare the injection site experience of two semaglutide delivery systems. Participants received two single subcutaneous doses of 0.25 mg semaglutide on one day, administered at least 30 minutes apart, one in each side of the stomach. The study compared the DV3396 pen-injector with semaglutide formulation D against the PDS290 pen-injector with semaglutide formulation B. Participants remained in the clinic for one day, with a follow-up phone call 4-5 weeks post-injection to assess the primary endpoint of injection site pain and discomfort.

The provided abstract describes the study design and objectives but does not include any results or findings regarding the comparison of injection site pain between the different semaglutide solutions or pen devices. Therefore, specific data, percentages, or p-values from the study's outcomes cannot be reported here.